Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
Using GLP-1RAs instead of insulin cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and saved US$19,391 and US$10,293, respectively, from the healthcare sector perspective
Liraglutide (Saxenda, Victoza) Liraglutide is another GLP-1 agonist, marketed as Saxenda for weight management and Victoza for type 2 diabetes
Xu W-N, Zheng H-L, Yang R-Z, Jiang L-S, Jiang S-D
Stability Characteristics Reported in the Literature BPC-157 is described in the source literature as unusually stable for a peptide of its length
US$ 24.91
US$ 25.85
US$ 28.04
